Surrozen named Andrew Maleki as its chief financial officer.
Maleki will succeed Charles Williams, who has been working as both finance and operating chief. Williams will now serve solely as chief operating officer, the biotechnology company said Friday.
Williams will intensify his focus on strategic initiatives and corporate development in his narrowed role.
Maleki has worked in biotechnology for more than 10 years and most recently led corporate development and program leadership at Lassen Therapeutics.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
November 07, 2025 18:23 ET (23:23 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments